Cargando…

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia

SIMPLE SUMMARY: Advances in immunophenotyping and molecular techniques have allowed for the development of more sensitive diagnostic tests in acute leukemia. These techniques can identify low levels of leukemic cells (quantified as 10(−4) to 10(−6) ratio to white blood cells) in patient samples. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azenkot, Tali, Jonas, Brian A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330895/ https://www.ncbi.nlm.nih.gov/pubmed/35892893 http://dx.doi.org/10.3390/cancers14153634

Ejemplares similares

Measurable residual disease in childhood B-cell acute lymphoblastic leukemia
por: Gale, Robert Peter
Publicado: (2022)

Measurable Residual Disease in High-Risk Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2022)

Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
por: Roloff, Gregory W., et al.
Publicado: (2017)

Improved detection of measurable residual disease in acute myeloid leukemia
por: Zhang, Xuan, et al.
Publicado: (2023)

Acute myeloid leukemia: leukemia stem cells write a prognostic signature
por: Gudgin, Emma J, et al.
Publicado: (2011)

The impact of venetoclax based regimens in the preemptive of measurable residual disease in acute myeloid leukemia
por: Fang, Qiuyun, et al.
Publicado: (2022)

Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia
por: Jentzsch, Madlen, et al.
Publicado: (2019)

Measurable residual disease in chronic myeloid leukemia
por: Branford, Susan, et al.
Publicado: (2022)

Delving the depths of measurable residual disease negativity in acute myeloid leukemia
por: Freeman, Sylvie D.
Publicado: (2022)

The present and future of measurable residual disease testing in acute myeloid leukemia
por: Blachly, James S., et al.
Publicado: (2022)

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia
por: Yoest, Jennifer M., et al.
Publicado: (2020)

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
por: Aitken, Marisa J. L., et al.
Publicado: (2021)

Role of Measurable Residual Disease in Older Adult Acute Myeloid Leukemia
por: Li, Xueyao, et al.
Publicado: (2023)

Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
por: Röhnert, Maximilian A., et al.
Publicado: (2022)

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
por: Pratz, Keith W., et al.
Publicado: (2022)

Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma
por: Leahey, Ann-Marie, et al.
Publicado: (2021)

How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?
por: Short, Nicholas J., et al.
Publicado: (2019)

Prognostic importance of the fusion partners and measurable residual disease in patients with acute myeloid leukemia who harbor 11q23/KMT2A alterations
por: Mrózek, Krzysztof
Publicado: (2023)

Rewiring of the Transcription Factor Network in Acute Myeloid Leukemia
por: Assi, Salam A, et al.
Publicado: (2019)

Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia
por: Dillon, Laura W., et al.
Publicado: (2019)

Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns
por: Božić, Tanja, et al.
Publicado: (2021)

Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection
por: Srinivasan Rajsri, Kritika, et al.
Publicado: (2023)

Taking the STING out of acute myeloid leukemia through macrophage-mediated phagocytosis
por: Dalton, William Brian, et al.
Publicado: (2022)

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications
por: Del Principe, Maria Ilaria, et al.
Publicado: (2016)

Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia
por: Karol, Seth E., et al.
Publicado: (2023)

Leukemia Stem Cell Frequency at Diagnosis Correlates With Measurable/Minimal Residual Disease and Impacts Survival in Adult Acute Myeloid Leukemia
por: Kamel, Azza M., et al.
Publicado: (2022)

Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia
por: Patkar, Nikhil, et al.
Publicado: (2018)

Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia
por: Buccisano, Francesco, et al.
Publicado: (2018)

Measurable Residual Disease Testing Using Next-Generation Sequencing in Acute Myeloid Leukemia
por: Kim, Seon Young, et al.
Publicado: (2023)

Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study
por: Scott, Stuart, et al.
Publicado: (2023)

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia
por: Vonk, Christian M., et al.
Publicado: (2021)

PB1767: CHALLENGES IN MACHINE LEARNING-BASED DETECTION OF MEASURABLE RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Thielecke, Lars, et al.
Publicado: (2023)

Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
por: Nilsson, Malin S., et al.
Publicado: (2019)

Angiogenesis and Minimal Residual Disease in Patients with Acute Myeloid Leukemia
por: Nematollahi, Pardis, et al.
Publicado: (2020)

Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia
por: Patkar, Nikhil, et al.
Publicado: (2019)

Diagnostic and Treatment Obstacles in Acute Myeloid Leukemia: Social, Operational, and Financial
por: Genç, Emine Eylem, et al.
Publicado: (2023)

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia
por: Gui, Gege, et al.
Publicado: (2023)

Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome
por: Pan, Jonathan, et al.
Publicado: (2020)

Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context
por: Patkar, Nikhil, et al.
Publicado: (2019)

Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors
por: Narlı Özdemir, Zehra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oa2cpkutm0vkkf3k5gqfhrplps